Are β-blockers really necessary after a heart attack if your heart function is normal? A new study says maybe not.
We’ve long known that β-blockers are lifesavers for heart attack patients with weakened heart function. But what about those whose hearts pump relatively well after a heart attack? A recent meta-analysis published in JAMA Cardiology (https://jamanetwork.com/journals/jamacardiology/fullarticle/10.1001/jamacardio.2025.4923?guestAccessKey=8daba73f-1008-483a-b5f2-27ae676d0bbb&utmsource=forthemedia&utmmedium=referral&utmcampaign=ftmlinks&utmcontent=tfl&utmterm=010726) challenges the routine use of these medications in this specific group. And this is the part most people miss: while β-blockers are undeniably crucial for those with reduced heart function, their benefits for patients with preserved left ventricular ejection fraction (LVEF) are far less clear.
Researchers pooled data from four major clinical trials—CAPITAL-RCT, REDUCE-AMI, REBOOT-CNIC, and BETAMI-DANBLOCK—involving nearly 20,000 patients. These trials focused on individuals who had experienced a heart attack but maintained an LVEF above 40%. Interestingly, the results were inconsistent. For instance, while REBOOT-CNIC found no significant benefit, BETAMI-DANBLOCK reported some positive effects. However, when the data were combined and analyzed using the Mantel-Haenszel method, the meta-analysis revealed no significant differences in key outcomes like cardiovascular mortality, heart failure, or unplanned revascularization between those taking β-blockers and those who weren’t.
But here's where it gets controversial: Could it be that modern treatments like early revascularization and optimized medical therapy have already maximized the benefits, leaving little room for β-blockers to make a difference in this population? The study authors suggest this might be the case, pointing to a potential 'ceiling effect' where additional interventions offer diminishing returns. This raises important questions about the necessity of β-blockers in patients with preserved LVEF, especially considering the potential side effects and costs associated with long-term medication use.
The study isn’t without its limitations. It relied on aggregate data from published trials rather than individual patient data, which restricted the ability to perform detailed subgroup analyses. Additionally, the number of eligible studies was limited, as many trials weren’t designed to specifically address outcomes in patients with LVEF above 50%. Still, the findings are compelling enough to warrant further investigation.
What do you think? Should we reconsider the routine prescription of β-blockers for heart attack patients with preserved heart function? Or is it too soon to change clinical practice based on these findings? Let us know in the comments below. For now, the authors emphasize the need for larger, more targeted studies to better define the role of β-blockers in this population and identify any subgroups that might still benefit from this treatment.
Stay informed on the latest in clinical care and health economics—subscribe to AJMC for expert insights delivered straight to your inbox.
